24/7 Market News Snapshot 07 January, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)

January 7, 2025

DENVER, Colo., 07 January, 2025 (247marketnews.com) – (NASDAQ:CING) are discussed in this article.
Cingulate Inc. is witnessing a notable surge in its stock performance, trading at $5.33 in the pre-market session, reflecting a remarkable increase of 7.26% from the previous close of $4.97. This surge indicates heightened buying interest among investors, evidenced by a trading volume of 820.70K shares. Such upward momentum hints at positive market sentiment, possibly influenced by recent company developments and anticipation of forthcoming announcements. Analysts will be vigilant in monitoring price levels and trading volumes to assess the sustainability of this bullish trend, as continued buying pressure may signal further upside potential in upcoming sessions.

In conjunction with its stock performance, Cingulate has reached a critical milestone in the development of its ADHD treatment, CTx-1301, by successfully completing the final FDA-required food effect study. This essential trial assessed the pharmacokinetics of CTx-1301, a dexmethylphenidate formulation, under varied dietary conditions. Notably, the study revealed no serious adverse events, bolstering the candidate’s safety profile.

CTx-1301 aims to be the first true once-daily stimulant for ADHD, utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) platform, which enables a consistent and effective release of medication throughout the day. Previous studies have indicated its efficacy in both fed and fasted states, with this recent investigation conducted using a higher dosage to validate the formulation’s adaptability.

Chairman and CEO Shane J. Schaffer emphasized this achievement as a pivotal moment for the company, highlighting the importance of providing a treatment that maintains effectiveness without regard for meal timing. Cingulate plans to release detailed bioavailability results later this year and intends to submit a New Drug Application (NDA) by mid-2025, signaling its ongoing commitment to enhancing ADHD management and improving overall patient outcomes. As the company continues to innovate, its efforts hold promise for addressing significant treatment challenges both in ADHD and potentially broader therapeutic areas.

Related news for (CING)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.